⌘K
t
Diaceutics PLC held its Annual General Meeting on June 18, 2025. All eleven proposed resolutions were passed by shareholders, including the re-election of Cheryl MacDiarmid, Jordan Clark, and Nick Roberts as directors, and the re-appointment of Ernst & Young as auditors. The "For" votes for the resolutions ranged from 83.09% to 99.99% of the total votes cast for each resolution.
| Date | 18 Jun 2025 |
| Time | 12:00:01 |
| Category | AGMs and other meetings |
| ID | 3999N |
Diaceutics PLC - Results of AGM
New York, Belfast and London, 18 June 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed. The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com
|
Resolution |
For (excluding at Chair's discretion) |
Against |
Total votes cast |
Withheld |
|||
|
|
|
Number of votes |
% |
Number of votes |
% |
Number of votes |
Number of votes |
|
1 |
Ordinary resolution to receive To receive and consider the Company's financial statements for the financial year ended 31 December 2024 together with the directors' report and the auditors' report on those annual accounts |
54,937,420 |
99.99% |
577 |
0.01% |
54,937,997 |
Nil |
|
2 |
Ordinary resolution to approve the directors' remuneration report |
44,895,272 |
83.09% |
9,136,725 |
16.91% |
54,937,997 |
906,000 |
|
3 |
Ordinary resolution to re-elect Cheryl MacDiarmid as a director of the Company |
54,937,420 |
99.99% |
577 |
0.01% |
54,937,997 |
Nil |
|
4 |
Ordinary resolution to re-elect Jordan Clark as a director of the Company |
51,811,362 |
99.98% |
11,300 |
0.02% |
54,937,997 |
3,115,335 |
|
5 |
Ordinary resolution to re-elect Nick Roberts as a director of the Company |
51,639,642 |
99.65% |
183,020 |
0.35% |
54,937,997 |
3,115,335 |
|
6 |
Ordinary resolution to re-appoint Ernst & Young as auditors of the Company |
54,925,512 |
99.98% |
12,485 |
0.02% |
54,937,997 |
Nil |
|
7 |
Ordinary resolution to authorise the directors to determine the remuneration of the auditors |
54,937,420 |
99.99% |
577 |
0.01% |
54,937,997 |
Nil |
|
8 |
Ordinary resolution to authorise the directors to allot ordinary shares |
54,905,822 |
99.94% |
32,175 |
0.06% |
54,937,997 |
Nil |
|
9 |
Special resolution to authorise the directors to dis-apply statutory pre-emption rights pursuant to section 570 of the Companies Act 2006 |
53,670,136 |
99.92% |
44,461 |
0.08% |
54,937,997 |
1,223,400 |
|
10
|
Special resolution to authorise the directors to make market purchase of its ordinary shares |
52,510,452 |
99.99% |
577 |
0.01% |
54,937,997 |
2,426,968 |
|
11 |
Ordinary resolution to approve The Diaceutics Unapproved Share Option Plan |
51,312,153 |
93.40% |
3,625,844 |
6.60% |
54,937,997 |
Nil |
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.